Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML

Despite increasing understanding of the pathobiology of acute myeloid leukemia (AML), outcomes remain dismal particularly for patients over the age of 60 years, a population enriched for therapy-related AML (tAML) and secondary AML (sAML). For decades, the standard of care for AML has been the combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Evan C, Fathi, Amir T, Brunner, Andrew M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003284/
https://www.ncbi.nlm.nih.gov/pubmed/29928134
http://dx.doi.org/10.2147/OTT.S141212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003284/
https://www.ncbi.nlm.nih.gov/pubmed/29928134
http://dx.doi.org/10.2147/OTT.S141212

Ejemplares similares